Board
Director
｜Chairwoman & CEO
Dr. Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J). She was Senior Director of Biologics Clinical Pharmacology at Centocor.
｜CSO
Dr. Lee was formerly the VP of DMPK at Millennium Pharmaceuticals (Takeda). He has over 41 years of experience in global pharmaceutical companies, with expertise in preclinical DMPK, toxicity assessment, and clinical trial strategy.
| Director
Top Taiwan Venture Capital Group (“TTVC”) is the largest and leading venture capital management team based in Taiwan with a fund size around $400 million
| Director
Isaiah Capital is devoted to investment and management in industries of innovative technology. One of its representatives has become BRIM’s angel investor since Series A and brought investors familiar with the capital market in Series D.
| Director
Audrey has worked in the accounting field for 35 years. She was the certified public accountant of many public companies such as Delta Electronics, Asus, WPG Holdings, etc. She is experienced in capital market, international financing, tax planning, M&A, corporate governance, and industrial development and managerial strategy. Audry has supported the IPO of countless biotech companies.
| Director
Philip is called “Investment Talent” in the financial world in Taiwan. He was the Chairman and General Manager of JPMorgan Fleming, and promoted as the Managing Director of JPMorgan in 2007. Philip joined Fubon Group in 2009 and engaged in senior management positions. Currently, Philip is the founder and chairman of both FN Capital Management Ltd and FN Management Consulting Co., Ltd.
Independent Director
| Independent Director
Daniel has more than 40 years of experience in US and Asia corporate governance and strategy. Since 2002, Daniel has focused on organizational efficiency development, professional development training, and coaching. Daniel received the China Management Talent award in 2007 and the World Outstanding Chinese Award in 2008.
| Independent Director
Larence specializes in drug metabolism and pharmacokinetics. He has more than 30 years of new drug development experience in global pharmas. Lawrence was the CEO of Taiwan’s Development Center of Biotechnology and holds an important role in the promotion of the biotechnology industry.
| Independent Director
Pear specializes in financial planning, managerial accounting and auditing, real estate appraisal, asset allocation planning, corporate structure, and intangible assets valuation.
